THE COMMUNITY ONCOLOGY ALLIANCE appointed new officers. Bruce Gould, of Northwest Georgia Oncology Centers in Marietta, Ga., was named president of COA.
JOHN CLEVELAND was named associate center director of basic science at Moffitt Cancer Center.
Current controversy over power morcellation points to the importance of multidisciplinary education and consultation, said Monica Bertagnolli, chief of the Division of Surgical Oncology at Brigham and Women's Hospital, and professor of surgery at Harvard Medical School.
The Cancer Letter asked David Challoner, emeritus vice president for health affairs at the University of Florida, to discuss the intricacies and effects of the FDA's 510(k) medical device approval process, and the parties that influence it.
On The Principles of SurgeryNoorchashm attributes his wife's complication in part to deficits in the gynecologists' surgical training.
On Oct. 17, 2013, a surgical instrument called a power morcellator tore into the uterus of Amy Reed, an anesthesiologist at Beth Israel Deaconess Medical Center, pulverizing what were believed to be benign fibroids.
FDA approved a new use for Lymphoseek Injection (technetium 99m tilmanocept), a radioactive diagnostic imaging agent, to determine the extent squamous cell carcinoma has spread in the body's head and neck region.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A dendritic cell-based immunotherapeutic vaccine increased median overall survival by about four months in a phase II placebo-controlled study in newly diagnosed glioblastoma multiforme.
In a phase III trial of patients with progressive radioiodine-refractory differentiated thyroid cancer, lenvatinib significantly extended progression-free survival compared to placebo.
